We’re looking forward to continuing our support for Fin Resources Ltd (ASX:FIN)
As no. 1 shareholders, Peak co-led the $3,750,000 raise and introduced a number of funds and new investors to the round.
FIN’s recently acquired Cabin Lake Project in Canada’s Northwest Territories has produced up some impressive historical high-grade hits, including 31.4m @ 15.2 g/t Au and 13.9m @ 13.21 g/t Au, with an imminent maiden ~1,500m diamond drilling campaign expected to commence in early March 2026.
Read more below in today’s article in The Australian:
FIN raises $3.75m ahead of gold drilling | The Australian
Across Markets…
The Australian sharemarket finished flat on Tuesday, after a late sell-off in health giant CSL on news that its chief executive is stepping down dragged the bourse into the red in the final minutes of trade.
The S&P/ASX 200 Index finished down 2.7 points, or less than 0.1 per cent, to 8867.4, after a sell-off in CSL and financials. Three out of the 11 sectors finished in the red.
News just before the close of trading that CSL chief executive Paul McKenzie is retiring after seven years sent the shares tumbling 5 per cent to a one-month low of $171.39, taking the ASX with it.
Gordon Naylor, a former senior CSL executive will step in as interim boss as of February 11.
“When the market saw that [McKenzie] is basically leaving immediately (which always scares the market) – the stock was smashed 5 per cent at 4.17pm and took 14.3 points off the ASX 200,” wrote Bell Potter’s Richard Coppleson in a report to clients.
Banks and insurers also weighed with ANZ falling more than 2 per cent to $36.71 while Westpac dropped 1.8 per cent to $39.28. Commonwealth Bank was modestly lower ahead of its results on Wednesday.
Uranium miners also continued to rebound as fears started to ease that AI demand would not trigger a boom in nuclear power. Paladin rose 5.5 per cent to $12.13 and Deep Yellow by 7.2 per cent to $2.55.
Elsewhere, miners finished mostly higher despite a tip in the gold and silver prices. BHP rose 1.1 per cent to $50.26, Rio Tinto 1.4 per cent to $162.59 and Newmont 1.6 per cent to $167.48
Source: AFR
EVE Health Group Launches Libbo ED Treatment and Men’s Health Platform
EVE Health Group (ASX: EVE) has announced the commercial launch of Libbo erectile dysfunction (ED) treatment on the Australian market, alongside the activation of an integrated platform for men’s health.
The platform provides education and support resources to help normalise ED as a common and readily treatable medical condition, reducing stigma, addressing misconceptions, and encouraging earlier engagement with appropriate care.
It incorporates patient education, digital onboarding, and clinical assessment with referrals to hubMed and TeleDocs Clinic for medical consultation, with prescriptions issued and fulfilled through Chemist2U for direct-to-patient delivery.
The platform also provides a foundation for future product extensions and expansion into additional therapeutic indications.
End-to-End Digital Pathway
EVE’s integrated ecosystem establishes an end-to-end digital pathway encompassing assessment, consultation, prescription, and fulfilment.
It is designed to support responsible prescribing, patient engagement, and scalable national access within a regulated healthcare framework.
By combining proprietary pharmaceutical products with digital engagement and clinical networks, the company is executing a vertically-integrated commercial model intended to accelerate market entry, support patient access, and build sustainable revenue streams in men’s health.
EVE chief executive officer Damian Wood said the Libbo launch represented a key milestone in the company’s transition from manufacturing and distribution into real-world patient access.
“With our digital platform now live and prescribing, and fulfilment pathways operational, we have established the core infrastructure required to support scalable national access in men’s health,” he said.
Under-Treated Condition
ED is an often under-treated condition which affects approximately one in five adult men and up to 40% of men over the age of 40.
Despite the availability of effective therapies, many men delay seeking treatment due to stigma, inconvenience, and concerns regarding privacy.
Mr Wood said Libbo’s oral dissolving film format offered patients a discreet, convenient and fast-acting alternative to tablets, potentially lifting compliance and patient satisfaction.
“This milestone reflects the disciplined execution of our commercial strategy and positions us to build a meaningful and sustainable presence in the men’s health sector,” he added.
Source: SmallCaps
Company: Fin Resources Ltd (ASX:FIN)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.0065
Today’s Price Change: $0.012 -7.69%
Company: Locksley Resources Ltd (ASX:LKY)
Sector: REE & Antimony/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Today’s Price Change: $0.180 +9.09%
Company: CuFe Ltd (ASX:CUF)
Sector: Copper/Mining
Deal Type: Placement
Latest Entry Price: $0.016 with 1:2 option, strike $0.025
Today’s Price Change: $0.048 Unchanged
Company: Tasman Resources Ltd (ASX:TAS)
Sector: Gold/Silver/Mining
Deal Type: Placement
Latest Entry Price: $0.0125 with 1:2 option, strike $0.02
Today’s Price Change: $0.041 +5.13%
Company: Tambourah Metals Ltd (ASX:TMB)
Sector: Gold/Mining
Deal Type: Placement
Latest Entry Price: $0.04
Today’s Price Change: $0.056 +1.82%
Company: Biotron Ltd (ASX:BIT)
Sector: Biotech
Deal Type: Placement
Latest Entry Price: $0.003 with 1:2 option, strike $0.02
Today’s Price Change: $0.003 -14.29%
Company: Eclipse Metals Ltd (ASX:EPM)
Sector: REE
Deal Type: Placement
Latest Entry Price: $0.015
Today’s Price Change: $0.023 Unchanged
Company: Neuren Pharmaceuticals Ltd (ASX:NEU)
Sector: Biotech
Deal Type: On-market purchase
Latest Entry Price: $1.20 – $1.50
Today’s Price Change: $13.51 +1.50%
Company: Dimerix Ltd (ASX:DXB)
Sector: Biotech
Deal Type: Rights Issue
Raise Amount: $800,000
Latest Entry Price: $0.08 with 1:1 option, strike $0.126
Today’s Price Change: $0.530 +6%
Sector: Blockchain
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.02 with 1:1 option $0.08 strike
Today’s Price Change: $0.027 +12.50%
Company: Critica Limited (ASX:CRI)
Sector: REE
Deal Type: Placement
Raise Amount: $1M
Latest Entry Price: $0.0075 with a 1:1 CRIO
Today’s Price Change: $0.028 Unchanged
Sector: Lithium
Deal Type: IPO
Raise Amount: $8.6M
Latest Entry Price: $0.09 with 1:2 PL3O
Today’s Price Change: $0.110 Unchanged
Sector: Cybersecurity & AI
Deal Type: Placement
Raise Amount: $1.7M
Latest Entry Price: $0.01 with 1:3 option $0.02 strike
Today’s Price Change: $0.007 Unchanged
Sector: Gold/Mining
Deal Type: Placement
Raise Amount: $2.3M
Latest Entry Price: $0.026 with 1:2 option $0.032 strike
Today’s Price Change: $0.044 Unchanged
If you would like more information on future Peak deals, please don’t hesitate to get in touch.
Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs. Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances. If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this information before making any decisions regarding the products. The Financial Services Guide (FSG) can be found at www.peakassetmanagement.com.au or by telephoning Peak on 1300 304 460
Comments are closed